Supplemental Table 2. Immune checkpoint therapy associated markers among KRAS-mutated tumors (A), comparison of these markers between KRAS G12C and all other subtypes (B) and further comparison between G12C, G12A and G13D subtypes (C). * represents p or q values <0.05.
No takes yet. Share an insight, caveat, or question.
Judd et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: